Brain+ (BRAINP) Status Update summary
Event summary combining transcript, slides, and related documents.
Status Update summary
25 Nov, 2025Strategic partnerships and sector expertise
Appointment of Anthony Hall, a leading figure in UK social care, as advisor, bringing deep regulatory and operational expertise.
Hall's experience includes leading digitalization at HC One and authoring influential policy reports.
His insights are shaping product alignment with Care Quality Commission (CQC) frameworks.
Regulatory landscape and market opportunity
CQC ratings significantly influence care home occupancy, investment, and staff recruitment.
The new Single Assessment Framework emphasizes person-centered care and observable outcomes.
Smaller care providers, which dominate the UK market, need accessible, structured toolkits for dementia care.
Product impact and commercial progress
Isla, a CST assistant, is positioned to help care homes meet CQC requirements and improve resident outcomes.
Recent months saw conversion of pipeline into three group contracts with care home groups, covering 1,300 residents across three regions.
Seven-week trials demonstrate measurable improvements in resident and carer well-being, supporting rapid expansion.
Latest events from Brain+
- Funding round supports U.K. launch and scaling of dementia therapy tech, aiming for 2026 break-even.BRAINP
Investor Update1 Feb 2026 - UK launch of digital dementia therapy advances; break-even targeted by end 2025.BRAINP
H1 202422 Jan 2026 - Clinically validated digital dementia care platform launches in U.K. with strong growth outlook.BRAINP
Investor Update20 Jan 2026 - Digital dementia care platform Ayla targets rapid U.K. growth, aiming for break-even by 2026.BRAINP
Investor Update12 Jan 2026 - Robust U.K. sales pipeline and imminent funding needs position for strong commercial growth.BRAINP
Investor Update11 Jan 2026 - 50% of rights issue secured, costs cut 35%, and U.K. sales pipeline prioritized for rapid growth.BRAINP
Investor Update9 Jan 2026 - UK dementia care expansion accelerates with rights issue and EUR 500,000 sales pipeline.BRAINP
Investor Update26 Dec 2025 - Net loss narrowed, Ayla launched in UK/Denmark, and UK sales pipeline exceeds €600,000.BRAINP
H2 202410 Sep 2025 - Strong UK care home traction, clinical validation, and a robust pipeline drive growth prospects.BRAINP
H1 20255 Sep 2025